Evidence map›Paper›PMID 33649516›Full record

ArticleThe pharmacogenomics journal2021

The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer.

Masaki Shiota, Shusuke Akamatsu, Shintaro Narita, Takayuki Sumiyoshi, Maki Fujiwara, Takeshi Uchiumi, Osamu Ogawa, Tomonori Habuchi, Masatoshi Eto

Abstract read
PubMed Publisher
In one paragraph

Article in The pharmacogenomics journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Single-cell analysis extracted CAFs-related genes to established online app to predict clinical outcome and radiotherapy prognosis of prostate cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Masaki Shiota *Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. shiota@uro.med.kyushu-u.ac.jp.ORCID http://orcid.org/0000-0002-3306-4858
Shusuke Akamatsu *Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Shintaro Narita *Department of Urology, Graduate School of Medicine, Akita University, Akita, Japan.
Takayuki SumiyoshiDepartment of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Maki FujiwaraDepartment of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-6354-2638
Takeshi UchiumiDepartment of Clinical Chemistry and Laboratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Osamu OgawaDepartment of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Tomonori HabuchiDepartment of Urology, Graduate School of Medicine, Akita University, Akita, Japan.
Masatoshi EtoDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kyoto University · JPKyushu University · JPAkita University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Missense polymorphism in HSD3B1, encoding 3β-hydroxysteroid dehydrogenase-1, was associated with outcome after abiraterone treatment. Other androgen-metabolizing enzymes may be involved in therapeutic effect in abiraterone. In this study, we investigated the significance of polymorphisms in genes involved in androgen and abiraterone metabolisms in prostate cancer patients treated with abiraterone. A total of 99 Japanese male castration-resistant prostate cancer patients treated with abiraterone between 2014 and 2018 were included. Genomic DNA was obtained from whole blood samples, and genotyping on SRD5A2 (rs523349), CYP17A1 (rs743572), CYP17A1 (rs2486758), and AKR1C3 (rs12529) was performed by PCR-based technique. Among the 99 patients, 32 (32.3%), 49 (49.5%), and 18 patients (18.2%) carried GG, GC, and CC alleles in SRD5A2, respectively. CC allele was associated with lower risk of treatment failure (hazard ratio, 0.43; 95% confidence interval, 0.20-0.87; P = 0.017) on multivariate analyses, compared with GG/GC alleles. In the combination model using HSD3B1 and SRD5A2 polymorphisms, compared with the combination of AA in HSD3B1 and GG/GC in SRD5A2, other combinations were associated with lower risk of treatment failure (hazard ratio, 0.34; 95% confidence interval, 0.17-0.62; P = 0.0003) on multivariate analyses. This study showed that SRD5A2 genetic variation was associated with the risk of treatment failure in abiraterone. Combinational use of genetic variation in HSD3B1 with SRD5A2 genetic variation augmented the ability of prognostic stratification.

Indexed as

3-Oxo-5-alpha-Steroid 4-DehydrogenaseAgedAged, 80 and overAllelesAndrostenesGenetic Association StudiesGenotypeHumansMaleMembrane ProteinsMiddle AgedMultienzyme ComplexesPolymorphism, GeneticProgesterone ReductaseProstatic Neoplasms, Castration-ResistantRetrospective Studies3 beta-hydroxysteroid oxidoreductase-delta(5) 3-ketosteroid isomerase3-Oxo-5-alpha-Steroid 4-DehydrogenaseabirateroneAndrostenesMembrane ProteinsMultienzyme ComplexesProgesterone ReductaseSRD5A2 protein, humanSteroid Isomerases

Identifiers

PMID33649516
OpenAlexW3135591602

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.